Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the ...

To correct high blood pressure of the pulmonary artery, which can arise from congenital defects of the heart, an artificial heart ucan cost upwards of $190,000. Heart disease accounted for about one ...

Lindsay talks about the difficult road of managing a pulmonary arterial hypertension diagnosis, and how a newly discovered medication helped secure her future.

NOTCH3-ECD is a specific IPAH biomarker, Cloud-Clone’s SEL147Hu ELISA Kit powers this breakthrough HUSTON, TX, UNITED STATES, March 17, 2026 /EINPresswire.com/ — A groundbreaking study published in ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension, with specific patient selection ...

BACKGROUND: Right ventricular failure drives both morbidity and mortality in pulmonary arterial hypertension (PAH), but the mechanism of transition from compensated right ventricle (cRV) to ...

Pulmonary hypertension is characterized by increased BP in the pulmonary vasculature You will want your patients to consult a specialist to slow progression of this debilitating disease. Here's what ...

Gossamer Bio reported last month that its only late-stage candidate failed a Phase 3 study in pulmonary arterial hypertension ...

Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women. Pulmonary ...

This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello, and welcome to this podcast series. I'm Dr Vallerie McLaughlin, the Kim A. Eagle Endowed Professor of Cardiovascular ...

Panelists discuss how prostacyclin pathway treatments remain important but challenging due to significant side effects and delivery complexity, with sotatercept potentially reducing reliance on ...

This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello and welcome to this Medscape InDiscussion on pulmonary arterial hypertension (PAH). Our topic today is the very important ...